PARG-IN-4 manufacturers
- PARG-IN-4
-
- $215.00
-
2026-05-11
- CAS:2988890-20-4
- Purity: 98.51%
- Supply Ability: 10g
|
| | PARG-IN-4 Basic information |
| Product Name: | PARG-IN-4 | | Synonyms: | PARG-IN-4;1H-Indazole-6-sulfonamide, 1-[5-(difluoromethyl)-1,3,4-thiadiazol-2-yl]-4-[(3S,5S)-3,5-dimethyl-1-piperazinyl]-N-(1-methylcyclopropyl)-;PARG inhibitor;1-(5-(Difluoromethyl)-1,3,4-thiadiazol-2-yl)-4-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(1-methylcyclopropyl)-1H-indazole-6-sulfonamide;IDE161 | | CAS: | 2988890-20-4 | | MF: | C20H25F2N7O2S2 | | MW: | 497.59 | | EINECS: | | | Product Categories: | | | Mol File: | 2988890-20-4.mol |  |
| | PARG-IN-4 Chemical Properties |
| Boiling point | 680.7±65.0 °C(Predicted) | | density | 1.65±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(Predicted) | | pka | 11.45±0.20(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | PARG-IN-4 Usage And Synthesis |
| Uses | PARG-IN-4 (Formula (A)) is an orally active and cell-permeable PARG inhibitor. PARG-IN-4 effectively inhibits tumor growth in mouse models. PARG-IN-4 can be used in cancer research[1]. | | References | [1] Paul A Barsanti, et al. Piperazine substituted indazole compounds as inhibitors of parg. Patent WO2023183850A1. |
| | PARG-IN-4 Preparation Products And Raw materials |
|